NCT03597594View on ClinicalTrials.gov

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Severe Combined Immunodeficiency
Interventions
DRUG

Anti-thymocyte globulin (rabbit)

given intravenously

DRUG

Busulfan

given intravenously

DRUG

Fludarabine

given intravenously

DRUG

Thiotepa

given intravenous infusion

DEVICE

CliniMACS

The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

OTHER

Donor Lymphocyte Infusion

given intravenous infusion

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER